Glioblastoma multiforme - An overview

Wspolczesna Onkologia

Volumn 18, Issue 5, 2014, Pages 307-312

  Urbanska, Kaja ^a   Sokolowska, Justyna ^a   Szmidt, Maciej ^a   Sysa, Pawel ^a  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Brain; Etiology; Glioblastoma multiforme; Risk factors; Treatment; Tumor

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; TEMOZOLOMIDE;

ATAXIA; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL FEATURE; DIPLOPIA; DIZZINESS; FAINTNESS; FINE NEEDLE ASPIRATION BIOPSY; GLIOBLASTOMA; HEADACHE; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; REVIEW; RNA INTERFERENCE; VISUAL DISORDER;

EID: 84918841199     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.40559     Document Type: Review

References (86)

1. Zukiel R, Piestrzeniewicz R, Nowak S, Jankowski R, Wieloch M. Historia leczenia operacyjnego guzow mozgu. Neuroskop 2004; 6: 9-19.
2. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H, Unterberg A, Herold-Mende C. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006; 118: 2182-9.
3. Moore MP, Bagley RS, Harrington ML, Gavin PR. Intracranial tumours. Vet Clin North Am Small Anim Pract 1996; 26: 759-77.
4. Kabat GC, Etgen AM, Rohan TE. Do steroid hormones play a role in the etiology of glioma? Cancer Epidemiol Biomarkers Prev 2010; 19: 2421-7.
5. Tso CL, Freije WA, Day A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006; 66: 159-67.
6. Cvetkoiv-Doži D, Skender-Gazibara M, Doži S. Morphological and molecular features of diffuse infiltrating astrocytoma. Arch Oncol 2004; 12: 38-9.
7. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999; 1: 44-51.
8. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002; 21: 3511-26.
9. Mahvash M, Hugo HH, Maslehaty H, Mehdorn HM, Stark AM. Glioblastoma multiforme in children: report of 13 cases and review of the literature. Pediatr Neurol 2011; 45: 178-80.
10. Winters JL, Wilson D, Davis DG. Congenital glioblastoma multiforme: a report of three casus and a review of the literature. J Neurol Sci 2001; 1: 13-9.
11. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
12. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2: 494-503.
13. Houben MP, van Duijn CM, Coebergh JW, Tijssen CC. Gliomas: the role of environmental risk factors and genetic predisposition. Ned Tijdschr Geneeskd 2005; 149: 2268-72.
14. Daniels LB, Shaya M, Nordberg ML, Shorter CD, Fowler M, Nanda A. Glioblastoma multiforme in two non-nuclear family members. J La State Med Soc 2007; 159: 215-22.
15. Padmalatha C, Harruff RC, Ganick D, Hafez GB. Glioblastoma multiforme with tuberous sclerosis. Report of a case. Arch Pathol Lab Med 1980; 104: 649-50.
16. Grips E, Wentzensen N, Sutter C, et al. Glioblastoma multiforme as a manifestation of Turcot syndrome. Nervenarzt 2002; 73: 177-82.
17. Sanchez-Ortiga R, Boix Carreno E, Moreno-Perez O, Pico Alfonso A. Glioblastoma multiforme and multiple endocrine neoplasic type 2 A. Med Clin (Barc) 2009; 133: 196-7.
18. Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH. Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Report Med 2009; doi: 10.1155/2009/757898
19. Zhen L, Yufeng C, Zhenyu S, Lei X. Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. J Neurooncol 2010; 99: 165-76.
20. Moorthy RK, Rajshekhar V. Development of glioblastoma multiforme following traumatic cerebral contusion: case report and review of literature. Surg Neurol 2004; 61: 180-4.
21. Lam PY, Di Tomaso E, Ng HK, Pang JC, Roussel MF, Hjelm NM. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 2000; 14: 28-32.
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
23. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, Sarkar C. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurol India 2004; 52: 228-32.
24. Benson VS, Pirie K, Green J, Casabonne D, Beral V; Million Women Study Collaborators. Lifestyle factors and primary glioma and meningioma tumours in the million women study cohort. Br J Cancer 2008; 99: 185-90.
25. Cobbs CS. Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis. Herpesviridae 2011; 2: 10.
26. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62: 3347-50.
27. Wang J, Yao L, Zhao S, et al. Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. Cancer Biol Ther 2012; 13: 389-400.
28. Spinelli V, Chinot O, Cabaniols C, Giorgi R, Alla P, Lehucher-Michel MP. Occupational and environmental risk factors for brain cancer: a pilot case-control study in France. Presse Med 2010; 39: 35-44.
29. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors current concepts and review of the literature. Neuro Oncol 2012; 4: 278-99.
30. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130: 2596-606.
31. Lakhan SE, Harle L. Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature. J Med Case Rep 2009; 3: 87.
32. Hur H, Jung S, Jung TY, Kim IY. Cerebellar glioblastoma multiforme in an adult. J Korean Neurosurg Soc 2008; 43: 194-7.
33. de Castro-Costa CM, de Araujo RW, de Arruda MA, de Araujo PM, de Figueiredo EG. Increased intracranial pressure in a case of spinal cervical glioblastoma multiforme. Analysis of these two rare conditions. Arq Neuropsiquiatr 1994; 52: 64-8.
34. Jung WH, Choi S, Oh KK, Chi JG. Congenital glioblastoma multiforme - report of an autopsy case. J Korean Med Sci 1990; 5: 225-31.
35. Birbilis TA, Matis GK, Eleftheriadis SG, Theodoropoulou EN, Sivridis E. Spinal metastasis of glioblastoma multiforme: an uncommon suspect? Spine (Phila Pa 1976) 2010; 35: 264-9.
36. Lun M, Lok E, Gautam S, Wu E, Wong ET. The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol 2011; 105: 261-73.
37. Robert M, Wastie M. Glioblastoma multiforme: a rare manifestation of extensive liver and bone metastases. Biomed Imaging Interv J 2008; 4: e3.
38. Mujic A, Hunn A, Taylor AB, Lowenthal RM. Extracranial metastases of a glioblastoma multiforme to the pleura, small bowel and pancreas. J Clin Neurosci 2006; 13: 677-81.
39. Widjaja A, Mix H, Golkel C, et al. Uncommon metastasis of a glioblastoma multiforme in liver and spleen. Digestion 2000; 61: 219-22.
40. al-Rikabi AC, al-Sohaibani MO, Jamjoom A, al-Rayess MM. Metastatic deposits of a high-grade malignant glioma in cervival lymph nodes diagnosed by fine needle aspiration (FNA) cytology-case report and literature review. Cytopathology 1997; 8: 421-7.
41. Jamjoom AB, Jamjoom ZA, Ur-Rahman N, Al-Rikabi AC. Cervival lymph node metastasis from a glioblastoma multiforme in a child. Report of a case and review of the literature. Ann Saudi Med 1997; 17: 340-3.
42. Wallace CJ, Forsyth PA, Edwards DR. Lymph node metastases from glioblastoma multiforme. AJNR Am J Neuroradiol 1996; 17: 1929-31.
43. Tysnes BB, Mahesparan R. Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 2001; 53: 129-47.
44. Mentrikoski M, Johnson MD, Korones DN, Scott GA. Glioblastoma multiforme in skin: a report of 2 cases and review of the literature. Am J Dermatopathol 2008; 30: 381-4.
45. Schultz S, Pinsky GS, Wu NC, Chamberlain MC, Rodrigo AS, Martin SE. Fine needle aspiration diagnosis of extracranial glioblastoma multiforme: Case report and review of the literature. Cytojournal 2005; 2: 19.
46. Rickert CH, Riemenschneider MJ, Schachenmayr W, Richter HP, Bockhorn J, Reifenberger G, Paulus W. Glioblastoma with adipocyte- like tumor cell differentiation - histological and molecular features of a rare differentiation pattern. Brain Pathol 2009; 19: 431-8.
47. Linkous AG, Yazlovitskaya EM. Angiogenesis in glioblastoma multiforme: navigating the maze. Anticancer Agents Med Chem 2011; 11: 712-8.
48. Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J Neurosurg 1996; 85: 1078-84.
49. Aamir A, Ul-Haque A. Morphological spectrum of vascular changes in glioblastoma multiforme. I J Pathol 2006; 4: 1-5.
50. Kleihues P, Burger PC, Collins VP, Cavenee WK. Pathology and genetics of tumours of the nervous system. IARC Press, Lyon 2000.
51. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920-7.
52. Wilhelmsson U, Eliasson C, Bjerkvig R, Pekny M. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression. Oncogene 2003; 22: 3407-11.
53. Biernat W. Molekularne podoe procesu progresji zos̈liwos̈ci glejakow rozlanych os̈rodkowego ukadu nerwowego. Onkol Pol 1999; 2: 113-9.
54. Levine SA, McKeever PE, Greenberg HS. Primary cerebellar glioblastoma multiforme. J Neurooncol 1987; 5: 231-6.
55. Gee TS, Ghani AR, Idris B, Awang MS. Case report: a rare case of pediatric conus medularis glioblastoma multiforme. Med J Malaysia 2012; 67: 438-41.
56. Sanli AM, Turkoglu E, Dolgun H, Sekerci Z. Unusual manifestations of primary Glioblastoma Multiforme: A report of three cases. Surg Neurol Int 2010; 1: 87.
57. Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M. Primary glioblastoma multiforme in youngers patients: a single-instruction experience. Tumori 2006; 92: 407-11.
58. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26: 239-44.
59. Agrawal A. Butterfly glioma of the corpus callosum. J Cancer Res Ther 2009; 5: 43-5.
60. Katsetos CD, Draberova E, Legido A, Dumontet C, Draber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol 2009; 221: 505-13.
61. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification and grading of gliomas. Glia 1995; 5: 211-21.
62. Baba H, Nakahira K, Morita N, Tanaka F, Akita H, Ikenaka K. GFAP gene expression during development of astrocyte. Dev Neurosci 1997; 19: 49-57.
63. Messing A, Brenner M. GFAP: functional implications gleaned from studies of genetically engineered mice. Glia 2003; 43: 87-90.
64. Rutka JT, Murakami M, Dirks PB, et al. Role of glial filaments in cells and tumors of glial origin: a review. J Neurosurg 1997; 87: 420-30.
65. Dohan FC Jr, Kornblith PL, Wellum GR, Pfeiffer SE, Levine L. S-100 protein and 2',3'-cyclic nucleotide 3'-phosphohydrolase in human brain tumors. Acta Neuropathol 1977; 40: 123-8.
66. Schroder R, Bien K, Kott R, Meyers I, Vossing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol 1991; 82: 389-94.
67. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007; 5: 894-902.
68. Castro MG, Candolfi M, Kroeger K, et al. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011; 11: 155-80.
69. Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, Berens ME. NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia 2009; 11: 377-87.
70. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
71. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
72. Gerstner ER, Batchelor TT. Antiangiogenic therapy for glioblastoma. Cancer J 2012; 18: 45-50.
73. Specenier P. Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 2012; 12: 9-18.
74. Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011; 5: 117-29.
75. Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM, Keating AK. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 2012; 31: 4171-81. doi: 10.1038/onc.2011.588
76. Guo D, Wang B, Han F, Lei T. RNA interference therapy for glioblastoma. Expert Opin Biol Ther 2010; 10: 927-36.
77. Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med 2011; 208: 2657-73.
78. Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: A phase II clinical trial. World Neurosurg 2011; 7: 736-44.
79. Altiok N, Ersoz M, Koyuturk M. Estradiol induces JNK-dependent apoptosis in glioblastoma cells. Oncol Lett 2011; 2: 1281-5.
80. Pollo B. Neuropathological diagnosis of brain tumours. Neurol Sci 2011; 32: 209-11.
81. Barker FG 2nd, Chang SM, Larson DA, Sneed PK, Wara WM, Wilson CB, Prados MD. Age and radiation response in glioblastoma multiforme. Neurosurgery 2001; 49: 1288-97.
82. Suh SY, Leblanc TW, Shelby RA, Samsa GP, Abernethy AP. Longitudinal patient-reported performance status assessment in the cancer. J Oncol Pract 2011; 7: 374-81.
83. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents. Columbia Univ. Press, New York 1949.
84. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-51.
85. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10.
86. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, Seyfried TN. Metabolic management of glioblastoma multiforme using standard therapy together with arestricted ketogenic diet. Case report. Nutr Metab (Lond) 2010; 7: 33.